Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It?
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 5, p. 365, doi. 10.1007/s40261-023-01271-w
- By:
- Publication type:
- Article
Works matching IS 11732563 AND DT 2023 AND VI 43 AND IP 5
Results: 9
1
2
Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 5, p. 369, doi. 10.1007/s40261-023-01270-x
- By:
- Publication type:
- Article
3
Correction to: A Cost‑effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
4
Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 5, p. 359, doi. 10.1007/s40261-023-01268-5
- By:
- Publication type:
- Article
5
A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case–Control Study.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 5, p. 347, doi. 10.1007/s40261-023-01267-6
- By:
- Publication type:
- Article
6
Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 5, p. 315, doi. 10.1007/s40261-023-01266-7
- By:
- Publication type:
- Article
7
Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 5, p. 335, doi. 10.1007/s40261-023-01265-8
- By:
- Publication type:
- Article
8
Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 5, p. 325, doi. 10.1007/s40261-023-01260-z
- By:
- Publication type:
- Article
9
Correction to: A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice